$4.76
9.31% today
Nasdaq, Feb 05, 04:21 pm CET
ISIN
US00091E1091
Symbol
ABSI

Absci Corp Stock price

$4.35
+0.98 29.08% 1M
+0.77 21.51% 6M
+1.73 66.03% YTD
+0.36 9.02% 1Y
-2.85 39.58% 3Y
-11.65 72.81% 5Y
-11.65 72.81% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.65 17.57%
ISIN
US00091E1091
Symbol
ABSI
Sector
Industry

Key metrics

Market capitalization $499.62m
Enterprise Value $368.74m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 87.59
P/S ratio (TTM) P/S ratio 118.67
P/B ratio (TTM) P/B ratio 2.47
Revenue growth (TTM) Revenue growth -39.35%
Revenue (TTM) Revenue $4.21m
EBIT (operating result TTM) EBIT $-103.35m
Free Cash Flow (TTM) Free Cash Flow $-70.76m
Cash position $142.87m
EPS (TTM) EPS $-0.94
P/E forward negative
P/S forward 82.52
EV/Sales forward 60.91
Short interest 27.25%
Show more

Is Absci Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Absci Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Absci Corp forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Absci Corp forecast:

Buy
100%

Financial data from Absci Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4.21 4.21
39% 39%
100%
- Direct Costs 14 14
3% 3%
324%
-9.43 -9.43
32% 32%
-224%
- Selling and Administrative Expenses 23 23
4% 4%
547%
- Research and Development Expense 57 57
22% 22%
1,360%
-90 -90
17% 17%
-2,131%
- Depreciation and Amortization 14 14
3% 3%
324%
EBIT (Operating Income) EBIT -103 -103
14% 14%
-2,455%
Net Profit -98 -98
8% 8%
-2,320%

In millions USD.

Don't miss a Thing! We will send you all news about Absci Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Absci Corp Stock News

Neutral
GlobeNewsWire
14 days ago
VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY.
Positive
Seeking Alpha
23 days ago
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI's main drug candidate for IBD. However, ABS-201 for hair loss and ABS-301 for solid tumors offer additional sizeable TAMs if successful. ABSI's AI models and wet lab data seem quite promising for discovering further antibodies that could be highly differen...
Neutral
GlobeNewsWire
26 days ago
Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics Collaboration combines Owkin's novel AI target discovery and agentic AI expertise with Absci's leading AI de novo design models to accelerate the discovery and design of potential first-in-...
More Absci Corp News

Company Profile

AbSci Corp. engages in the development of protein biomanufacturing technology. It offers SoluPro, an all-in-one protein expression platform which produces complex proteins using simplest and least expensive organism. The company was founded by Sean Mcclain and Mark Valasek in 2011 and is headquartered in Vancouver, WA.

Head office United States
CEO Sean McClain
Employees 156
Founded 2011
Website www.absci.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today